Image

Global Psychedelic Drugs Market – Industry Trends and Forecast to 2031

Pharmaceutical

Image

Global Psychedelic Drugs Market – Industry Trends and Forecast to 2031

  • Pharmaceutical
  • Upcoming Report
  • Apr 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Psychedelic Drugs Market – Industry Trends and Forecast to 2031

Market Size in USD Billion

CAGR :  % Diagram

Billion Billion
Diagram Forecast Period 2023–2031
Diagram Market Size (Base Year) USD 2.71
Diagram Market Size (Forecast Year) USD 7.35
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Psychedelic Drugs Market, By Source (Synthetic and Natural), Type (Empathogens, Dissociatives, and Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-MethylEnedioxyMethamphetamine, and Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, and Others), Route of Administration (Oral, Inhalation, and Injectable), End-User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031.

Psychedelic Drugs Market

Psychedelic Drugs Market Analysis and Size

The market for psychedelic drugs includes a range of substances classified as empathogens, dissociatives, and others. Empathogens such as MDMA can increase feelings of empathy and sociability, while dissociatives such as ketamine can create a sense of detachment from reality. Other psychedelics, such as psilocybin mushrooms and LSD, can change perception and cognition.

The global psychedelic drugs market size was valued at USD 2.71 billion in 2023 and is projected to reach USD 7.35 billion by 2031, with a CAGR of 13.3% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Source (Synthetic and Natural), Type (Empathogens, Dissociatives, and Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-MethylEnedioxyMethamphetamine, and Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, and Others), Route of Administration (Oral, Inhalation, and Injectable), End-User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy)

Countries Covered

U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America

Market Players Covered

Jazz Pharmaceuticals, Inc. (U.S.), Janssen Pharmaceuticals, Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Compass (U.S.), Verrian (Germany), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Avadel (Ireland), Celon Pharma SA (Poland), Cybin Corp. (Canada), GH Research (Ireland), Entheon Biomedical Corp (Canada), PharmaTher Holdings Ltd. (India), NRx Pharmaceuticals, Inc. (U.S.), and Usona Institute (U.S.)

Market Opportunities

  • Increasing Research Funding
  •  Collaborations Between Academia and Industry

Market Definition

Psychedelic drugs are substances that can cause changes in perception, mood, and cognition, often resulting in intense subjective experiences. Instances of these compounds include psilocybin (found in certain mushrooms), LSD, and MDMA. They mainly target serotonin receptors in the brain and are under investigation for their potential therapeutic benefits in treating mental health disorders, especially when used in supervised settings.                    

Psychedelic Drugs Market Dynamics

Drivers

  • Rising Support for Psychedelic Therapy

The healthcare sector is increasingly accepting psychedelic therapy, spurred by numerous clinical trials demonstrating the therapeutic promise of substances such as psilocybin and MDMA for conditions such as depression, PTSD, and addiction. This evolving attitude among healthcare professionals and regulatory bodies is facilitating the wider incorporation of psychedelic-assisted therapy into conventional healthcare approaches, fueling substantial market expansion.

  • Worldwide Shift Towards Psychedelic Legalization and Decriminalization 

Governments around the world are reassessing their policies on psychedelics, acknowledging their therapeutic potential in treating mental health disorders.This shift includes moves to decriminalize possession and even legalize medical and recreational use. These policy changes are creating new opportunities for research, development, and commercialization in the market and driving the market growth.

Opportunities

  • Collaborations Between Academia and Industry

Academic institutions contribute scientific research and expertise, while industry partners provide resources and insights for drug development, formulation, and commercialization. This collaboration accelerates scientific discoveries into innovative therapies, offering lucrative opportunities for both sectors amidst growing market demand.

  • Increasing Research Funding

Rising research funding facilitates extensive scientific investigations into therapeutic applications, safety profiles, and mechanisms of action of psychedelic compounds. This financial support fosters the identification of novel drug candidates and enhances existing treatments, attracting public and private investments and fueling market growth and expansion.

Restraints/Challenges

  • Cultural Obstacles

In areas dominated by conservative values or where the use of psychedelic drugs contradicts cultural norms or religious beliefs, the acceptance of these substances may be limited. This lack of acceptance could lead to reduced demand for psychedelic therapies, decreased willingness among healthcare professionals to prescribe them, and difficulties in regulatory approval processes, which can be a challenge for the market. 

  • Misuse and Public Safety Issues

Misuse, whether recreational or self-administered without medical supervision, can lead to adverse effects such as psychological distress or worsening of underlying mental health conditions. These events lead to doubt among regulators, healthcare professionals, and the public, disrupting the widespread acceptance of psychedelic therapies.

This psychedelic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the psychedelic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In September 2023, Cybin Inc. revealed a strategic partnership with Fluence, a renowned provider of continuing education in psychedelic therapy. This collaboration aims to bolster the expansion of the EMBARK training program for the CYB003 phase 3 trial
  • In October 2022, Numinus Wellness Inc., a leading mental health care company, launched a pioneering program offering Ketamine for treating chronic and serious medical conditions. Initially, this groundbreaking program was introduced in Numinus' clinics situated in Utah, British Columbia, and Quebec

Psychedelic Drugs Market Scope

The psychedelic drugs market is segmented on the basis of source, type, drugs, application, route of administration, end-user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Source

  • Synthetic
  • Natural

Type

  • Empathogens
  • Dissociatives
  • Others

Drugs

  • Gamma-Hydroxybutyric Acid
  • Ketamine
  • Psilocybin
  • Lysergic Acid Diethylamide (LSD)
  •  3,4-MethylEnedioxyMethamphetamine
  • Others

Application

  • Narcolepsy
  • Treatment Resistant Depression
  • Major Depressive Disorder
  • Opiate Addiction
  • Post-Traumatic Stress Disorder
  • Others

 Route of Administration

  • Oral
  • Inhalation
  • Injectable

End-User

  • Hospital
  • Speciality Clinics
  • Homecare
  • Others

 Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Psychedelic Drugs Market Regional Analysis/Insights

The psychedelic drugs market is analyzed and market size insights and trends are provided by country, source, type, drugs, application, route of administration, end-user, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the market due to the region's high prevalence of mental disorders, and ongoing research and development efforts drive market growth. This sustained leadership highlights North America's crucial role in influencing the direction of the global psychedelic drugs market.

Asia-Pacific is expected to witness significant growth during the forecast period due to expanding healthcare infrastructure and growing public awareness. As the region invests in mental health services and education, along with increasing acceptance of psychedelic therapies, it is emerging as a key contributor to the market's global expansion and development.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The psychedelic drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for psychedelic drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the psychedelic drugs market. The data is available for historic period 2016-2021.

Competitive Landscape and Psychedelic Drugs Market Share Analysis

The psychedelic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

  • Jazz Pharmaceuticals, Inc. (U.S.),
  • Janssen Pharmaceuticals, Inc. (U.S.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Compass (U.S.)
  • Verrian (Germany)
  • Pfizer Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Avadel (Ireland)
  • Celon Pharma SA.(Poland)
  • Cybin Corp. (Canada)
  • GH Research (Ireland)
  • Entheon Biomedical Corp (Canada)
  • PharmaTher Holdings Ltd. (India)
  • NRx Pharmaceuticals, Inc. (U.S.)
  • Usona Institute (U.S.)Top of Form


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

Rising Support for Psychedelic Therapy & Worldwide Shift Towards Psychedelic Legalization and Decriminalization are the growth drivers of the psychedelic drugs market.
Source, type, drugs, application, route of administration, end-user, and distribution channel are the factors on which the psychedelic drugs market research is based.
The major companies in the psychedelic drugs market are Jazz Pharmaceuticals, Inc. (U.S.), Janssen Pharmaceuticals, Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Compass (U.S.), Verrian (Germany), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Avadel (Ireland), Celon Pharma SA (Poland), Cybin Corp. (Canada), GH Research (Ireland), Entheon Biomedical Corp (Canada), PharmaTher Holdings Ltd. (India), NRx Pharmaceuticals, Inc. (U.S.), and Usona Institute (U.S.).
The psychedelic drugs market size will be worth USD 7.35 billion by 2031.
The growth rate of the psychedelic drugs market is 13.3%.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials